Bionano Genomics (NASDAQ:BNGO) specializes in offering tools and services based on its Saphyr system for the analysis of chromosomes, known as cytogenomics. This technology provides researchers and clinicians with a deeper understanding of genetics and the structure of the genome, aiding in the detection of diseases and disorders that conventional cytogenetics might miss. Focused on revolutionizing the way genomic research is conducted, Bionano aims to unlock critical genomic information with high-throughput and high-resolution capabilities. The company is dedicated to advancing the field of genomics, striving to make its cutting-edge technology an integral part of research and clinical diagnostics. By pushing the boundaries of genomic analysis, Bionano's objective is to contribute to the development of personalized medicine and improve healthcare outcomes.